Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 4:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 99 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) Clear all

Conditions: Fatty Liver
Interventions: Polyunsaturated fatty acid (Opti-EPA), Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Age-related Macular Degeneration
Interventions: Omega-3 fatty acids (fish oil), Vitamin D3, Vitamin D3 placebo, Fish oil placebo; Drug · Dietary Supplement
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 50 Years and older
Enrollment: 25,871 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertriglyceridemia
Interventions: AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo; Drug
Lead sponsor: Amarin Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 18
States / cities: Sacramento, California • Golden, Colorado • Miami, Florida + 13 more

Conditions: Fractures
Interventions: Vitamin D3 placebo, Fish oil placebo, omega-3 fatty acids (fish oil), Vitamin D3; Dietary Supplement · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 50 Years and older
Enrollment: 25,871 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cardiovascular Disease
Interventions: Vitamin D3, Omega-3 fatty acids (fish oil), Fish oil placebo, Vitamin D3 placebo; Dietary Supplement · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 50 Years and older
Enrollment: 25,119 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Pain Following Thermal Burn Injury
Interventions: Omega-3 fatty acids (fish oil), Vitamin D3 (cholecalciferol), Vitamin D3 (cholecalciferol) placebo, Omega-3 fatty acid placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Overactive Bladder
Interventions: Omega 3 Fatty Acid, Placebo; Drug
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Stage 0 Breast Carcinoma, Breast Neoplasms, Stage I Breast Carcinoma, Stage II Breast Carcinoma, Stage III Breast Carcinoma
Interventions: Metformin, Omega-3 fatty acids; Drug
Lead sponsor: Katherine D. Crew; Other
Eligibility: 21 Years to 75 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Inflammation; Muscle
Interventions: ESPO-572®, PCSO-524®; Dietary Supplement
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Bloomington, Indiana

Conditions: Preterm Birth
Interventions: 17 alpha-Hydroxyprogesterone Caproate and Omega-3 supplement, 17 alpha-hydroxy progesterone caproate and Placebo supplement; Drug
Lead sponsor: The George Washington University Biostatistics Center; Other
Eligibility: Female only
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 12
States / cities: Birmingham, Alabama • Chicago, Illinois • Detroit, Michigan + 9 more

Conditions: Psychosis
Interventions: Omega-3 Long Chain Fatty Acid, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 12 Years to 30 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 8
States / cities: Los Angeles, California • San Diego, California • New Haven, Connecticut + 5 more

Conditions: Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Bipolar Disorder, Psychosis NOS
Interventions: Risperidone, Omega-3 capsules, Placebo; Drug
Lead sponsor: Delbert Robinson; Other
Eligibility: 15 Years to 40 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Glen Oaks, New York

Conditions: Breast Cancer
Interventions: Omega-3 fatty acid supplement; Dietary Supplement
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Systemic Lupus Erythematosus
Interventions: Omega-3, flow-mediated dilation of the brachial artery, corn starch; Drug · Device · Other
Lead sponsor: Michelle Petri M.D.,MPH; Other
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Bipolar Disorder
Interventions: Experimental Diet, Comparator Diet; Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Obesity, Hypertriglyceridemia, Insulin Resistance, Hypertension
Interventions: Fish Oil, Flaxseed Oil, Placebo; Dietary Supplement
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Stanford, California

Conditions: Autism Spectrum Disorders, Hyperactivity
Interventions: Omega-3 Fatty Acids, Placebo; Drug · Other
Lead sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Other
Eligibility: 5 Years to 8 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Multiple Locations, Maryland

Conditions: Aging
Interventions: Vitamin D3 (cholecalciferol), fish oil; Dietary Supplement · Drug
Lead sponsor: Augusta University; Other
Eligibility: 50 Years and older
Enrollment: 1,054 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: COPD, Asthma, Pulmonary Function, Pneumonia
Interventions: Vitamin D3, fish oil, Vitamin D3 placebo, Fish oil placebo; Dietary Supplement
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 50 Years and older
Enrollment: 25,871 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: High Triglyceride Level, HIV Infection
Interventions: Lovaza; Drug
Lead sponsor: Tufts University; Other
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cardiovascular Diseases
Interventions: AMR101, Placebo, Statin therapy; Drug
Lead sponsor: Amarin Pharma Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 8,179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 176
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 154 more

Conditions: Hypertriglyceridemia
Interventions: Omega-3-acid ethyl esters, Placebo; Drug
Lead sponsor: Babu Balagopal; Other
Eligibility: 10 Years to 17 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 3
States / cities: Wilmington, Delaware • Baltimore, Maryland • Philadelphia, Pennsylvania

Conditions: Lipoprotein Metabolism, PCSK9, Proteomics
Interventions: EPA-rich fish oil, DHA-rich fish oil; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Bioavailability
Interventions: EPA + DHA in SMEDS Formulation, Lovaza (active comparator; already FDA approved); Dietary Supplement · Other
Lead sponsor: Midwest Center for Metabolic and Cardiovascular Research; Other
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Boca Raton, Florida • Chicago, Illinois

Search by objective public record fields.

Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver

Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL)

Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL

VITamin D and OmegA-3 TriaL (VITAL): Fractures, Vitamin D and Genetic Markers

VITAL Rhythm Study

Vitamin D and n-3 Polyunsaturated Fatty Acids (PUFAs) to Prevent Chronic Pain Following Major Thermal Burn Injury

Oxybutynin and Omega-3 for OAB (Overactive Bladder)

Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer

Effectiveness of Two Different Forms of Marine Oil on Indirect Markers of Muscle Damage and Soreness in Untrained Men

Omega-3 Fatty Acid Supplementation to Prevent Preterm Birth in High Risk Pregnancies

NAPLS Omega-3 Fatty Acid Versus Placebo Study

Omega-3 Dietary Supplements in Schizophrenia

Altering Lipids for Tolerance of Aromatase Inhibitor Therapy

Efficacy of Fish Oil in Lupus Patients

Dietary Intervention for Bipolar Disorder

Effects of Omega-3 Fatty Acids on Markers of Inflammation

Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder

Effects of Vitamin D and Omega-3 Supplementation on Telomeres in VITAL

LungVITamin D and OmegA-3 Trial (lungVITAL)

The Impact of Omega Three Fatty Acids on Vascular Function in HIV

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin

Fish Oil Study for High Triglyceride Levels in Children

Comparison of EPA and DHA-Rich Fish Oils on Lipoprotein Metabolism In Adults

Bioavailability of EPA + DHA in a SMEDS Formulation